NO145691C - Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider

Info

Publication number
NO145691C
NO145691C NO750763A NO750763A NO145691C NO 145691 C NO145691 C NO 145691C NO 750763 A NO750763 A NO 750763A NO 750763 A NO750763 A NO 750763A NO 145691 C NO145691 C NO 145691C
Authority
NO
Norway
Prior art keywords
decapeptidamides
preparation
therapeutically effective
analogy procedure
analogy
Prior art date
Application number
NO750763A
Other languages
English (en)
Norwegian (no)
Other versions
NO750763L (en:Method
NO145691B (no
Inventor
Masahiko Fujino
Tsunehiko Fukuda
Susuma Shinagawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO750763L publication Critical patent/NO750763L/no
Publication of NO145691B publication Critical patent/NO145691B/no
Publication of NO145691C publication Critical patent/NO145691C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO750763A 1974-03-08 1975-03-07 Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider NO145691C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2744274A JPS5726506B2 (en:Method) 1974-03-08 1974-03-08

Publications (3)

Publication Number Publication Date
NO750763L NO750763L (en:Method) 1975-09-09
NO145691B NO145691B (no) 1982-02-01
NO145691C true NO145691C (no) 1982-05-12

Family

ID=12221217

Family Applications (1)

Application Number Title Priority Date Filing Date
NO750763A NO145691C (no) 1974-03-08 1975-03-07 Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider

Country Status (18)

Country Link
US (1) US3972859A (en:Method)
JP (1) JPS5726506B2 (en:Method)
AT (1) AT348693B (en:Method)
BE (1) BE826430A (en:Method)
CA (1) CA1072953A (en:Method)
CH (1) CH615661A5 (en:Method)
CS (1) CS186284B2 (en:Method)
DE (1) DE2509783C2 (en:Method)
DK (1) DK149862C (en:Method)
ES (1) ES435405A1 (en:Method)
FI (1) FI60859C (en:Method)
FR (1) FR2262995B1 (en:Method)
GB (1) GB1498048A (en:Method)
HU (1) HU174077B (en:Method)
NL (1) NL181658C (en:Method)
NO (1) NO145691C (en:Method)
SE (1) SE420718B (en:Method)
ZA (1) ZA751306B (en:Method)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU497512B2 (en) * 1975-04-15 1978-12-14 Ici Australia Limited Nona and deca-peptides
US4215038A (en) * 1978-10-16 1980-07-29 The Salk Institute For Biological Studies Peptides which inhibit gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4318905A (en) * 1980-06-23 1982-03-09 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues
ZA815447B (en) * 1980-08-29 1982-08-25 Salk Inst For Biological Studi Peptides affecting gonadal function
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU549053B2 (en) * 1981-12-28 1986-01-09 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
JPS58125819U (ja) * 1982-02-19 1983-08-26 名伸電機株式会社 積算電力量計用パツキン
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4663435A (en) * 1982-12-06 1987-05-05 Merck & Co., Inc. Bridged cyclic hexapeptide somatostatin analogs
US4581168A (en) * 1983-02-21 1986-04-08 Sanofi Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
ZA918168B (en) 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
DE69508985T2 (de) * 1994-02-21 1999-08-19 Takeda Chemical Industries Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
AU699748B2 (en) * 1994-05-10 1998-12-10 Hybritech Incorporated Recombinant HK2 polypeptide
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
EP1203761B1 (en) 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU731146C (en) 1996-05-01 2005-02-03 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
CA2208336A1 (en) * 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. A device structure for iontophoresis
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
WO1998059073A1 (en) 1997-06-20 1998-12-30 Mayo Foundation For Medical Education And Research Method for detection of breast cancer
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6087128A (en) * 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
EP1203014B1 (en) * 1999-08-06 2004-10-13 Genentech, Inc. Peptide antagonists of factor viia
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
DE60041564D1 (de) * 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
US7968080B2 (en) 2003-08-20 2011-06-28 The Regents Of The University Of California Somatostatin analogs with inhibitory activity to growth hormone release
EP1664082B1 (en) * 2003-09-18 2014-03-05 MacroGenics West, Inc. Kid3 and anti-kid3 antibodies
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
CN101432305B (zh) * 2004-06-07 2014-07-30 雷文生物技术公司 运铁蛋白受体抗体
US20060073152A1 (en) * 2004-10-05 2006-04-06 Genentech, Inc. Therapeutic agents with decreased toxicity
WO2006076584A2 (en) 2005-01-12 2006-07-20 Raven Biotechnologies, Inc. Kid31 and antibodies that bind thereto
JP2008538173A (ja) * 2005-01-31 2008-10-16 レイベン バイオテクノロジーズ，インコーポレイティド Ｌｕｃａ２およびそれに結合する抗体
CA2596273C (en) * 2005-02-02 2017-11-14 Raven Biotechnologies, Inc. Adam-9 modulators
US20060171952A1 (en) * 2005-02-02 2006-08-03 Mather Jennie P JAM-3 and antibodies that bind thereto
EP1846455A4 (en) 2005-02-03 2010-02-17 Raven Biotechnologies Inc ANTIBODY TO THE ONKOSTATIN M RECEPTOR
EP1790656A1 (en) * 2005-11-25 2007-05-30 Nanokem S.A. Solution-phase synthesis of leuprolide
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
US20110014287A1 (en) 2009-04-20 2011-01-20 Altman Gregory H Silk Fibroin Hydrogels and Uses Thereof
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012022210B1 (pt) 2010-03-04 2021-08-17 Macrogenics, Inc Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
UA115402C2 (uk) 2011-05-21 2017-10-25 Макродженікс, Інк. Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EP2557163A1 (en) 2011-08-12 2013-02-13 SymbioGruppe GmbH & Co KG Bacterially formed microcin S, a new antimicrobial peptide, effective against pathogenic microorganisms, e.g. enterohemorrhagic Escherichia coli (EHEC)
DK2748182T3 (en) 2011-08-23 2017-02-06 Harvard College Peptide nanoparticles and their applications
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SMT202100464T1 (it) 2013-03-14 2021-11-12 Macrogenics Inc Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
EP2978438A1 (en) 2013-03-29 2016-02-03 Centre National de la Recherche Scientifique (C.N.R.S.) Cgrp receptor agonist for hiv treatment or prevention
CN106573050B (zh) 2014-05-29 2021-09-24 宏观基因有限公司 特异性结合多种癌症抗原的三特异性结合分子和其使用方法
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP4450088A3 (en) 2015-07-30 2025-03-26 MacroGenics, Inc. Pd-1-binding molecules and methods of use thereof
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
KR102514317B1 (ko) 2016-04-15 2023-03-27 마크로제닉스, 인크. 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates

Also Published As

Publication number Publication date
HU174077B (hu) 1979-10-28
US3972859A (en) 1976-08-03
ES435405A1 (es) 1976-12-01
NL7502564A (nl) 1975-09-10
BE826430A (fr) 1975-09-08
SE7502520L (en:Method) 1975-09-09
NL181658C (nl) 1987-10-01
SE420718B (sv) 1981-10-26
GB1498048A (en) 1978-01-18
AU7859475A (en) 1976-08-26
JPS5726506B2 (en:Method) 1982-06-04
DK149862C (da) 1987-06-15
DK92775A (en:Method) 1975-09-09
FI60859B (fi) 1981-12-31
FI750682A7 (en:Method) 1975-09-09
FR2262995B1 (en:Method) 1978-07-28
AT348693B (de) 1979-02-26
ATA138075A (de) 1978-07-15
NO750763L (en:Method) 1975-09-09
FI60859C (fi) 1982-04-13
CA1072953A (en) 1980-03-04
DE2509783A1 (de) 1975-09-11
JPS50121277A (en:Method) 1975-09-23
NO145691B (no) 1982-02-01
NL181658B (nl) 1987-05-04
CS186284B2 (en) 1978-11-30
DK149862B (da) 1986-10-13
DE2509783C2 (de) 1983-02-17
ZA751306B (en) 1976-01-28
CH615661A5 (en:Method) 1980-02-15
FR2262995A1 (en:Method) 1975-10-03

Similar Documents

Publication Publication Date Title
NO145691C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme decapeptidamider
NO146200C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 16-oksygenerte prostansyrederivater
NO157933C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme cefemforbindelser.
NO149106C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive benzcykloamider
NO145075C (no) Kontinuerlig fremgangsmaate til fremstilling av alkoksysilaner
SE7513085L (sv) Forfarande for framstellning av etrar
NO143796C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme piperazinyliminorifamyciner
NO142303C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme oksazolderivater
SE421209B (sv) Analogiforfarande for framstellning av tienobensodiazepiner
NO152509C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme cephalosporinforbindelser
SE7506160L (sv) Forfarande for framstellning av n-cykloalkylmetyldekahydroisokinoline
NO141755C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme dotriacontapeptidamider
NO146022C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme benzofenonderivater
NO141894C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridobenzodiazepinoner
NO141262C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme tripeptider
NO143625C (no) Analogifremgangsmaate for fremstilling av 2-metoksy-benzamider
SE411453B (sv) Forfarande for framstellning av 3-fluorcefalosporiner
SE403477B (sv) Forfarande for famstellning av substituerade indoleniner
NO144604C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme histidinderivater
NO142907C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme fenylalkylaminer
NO144741C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiopyrano-pyrazoler
SE7511801L (sv) Forfarande for framstellning av ympsampolymerisat
NO153221C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 6-metoksy-alfa-karboksypenicilliner.
NO143501C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksom benzopyranforbindelse
NO145982C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme monokromon-forbindelser